Literature DB >> 27201727

Mcda Approach To Ranking Rare Diseases In Russia: Preliminary Results.

V K Fedyaeva1, V V Omelyanovsky1, O Rebrova2, N Khan1, E V Petrovskaya3.   

Abstract

Entities:  

Year:  2014        PMID： 27201727     DOI： 10.1016/j.jval.2014.08.1729

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  4 in total

Review 1.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

2.  Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.

Authors:  Carina Schey; Maarten Jacobus Postma; Paul F M Krabbe; Olekdandr Topachevskyi; Andrew Volovyk; Mark Connolly
Journal:  Front Public Health       Date:  2020-05-08

3.  Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).

Authors:  Lieven Annemans; Ségolène Aymé; Yann Le Cam; Karen Facey; Penilla Gunther; Elena Nicod; Michele Reni; Jean-Louis Roux; Michael Schlander; David Taylor; Carlo Tomino; Josep Torrent-Farnell; Sheela Upadhyaya; Adam Hutchings; Lugdivine Le Dez
Journal:  Orphanet J Rare Dis       Date:  2017-03-10       Impact factor: 4.123

4.  Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?

Authors:  Aleksandra Baran-Kooiker; Marcin Czech; Coen Kooiker
Journal:  Front Public Health       Date:  2018-10-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.